RxDoctor Payments Data

Thomas Biddison

Family Medicine · Los Angeles, CANPI 1669402327

Payments from drug & device makers

$6,624in general payments, 2019–2025

Across 161 payments — averaging $41.14 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Theratechnologies Inc.$2K
  • Gilead$2K
  • Viiv Healthcare Company$1K
  • Napo Pharmaceuticals Inc$490
  • Johnson & Johnson$363
  • EMD Serono, Inc.$294
  • plus $321 from 6 others

What the payments were for

  • Consulting fees$2,25034%
  • Speaking & faculty fees$1042%
  • Travel & lodging$220%
  • Food & beverage$4,24864%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$6,624 in reported general payments places this provider in the 90th percentile of 10,533 family medicine providers in California.

See all family medicine providers in California

Most prescribed under Part D

DrugClaimsCost to plans & patients
BiktarvyBictegrav/Emtricit/Tenofov Ala111$408,606
JulucaDolutegravir/Rilpivirine102$332,603
TriumeqAbacavir/Dolutegravir/Lamivudi63$242,113
OdefseyEmtricitab/Rilpiviri/Tenof Ala54$186,210
TivicayDolutegravir Sodium76$162,691
DescovyEmtricitabine/Tenofov Alafenam75$153,678
DovatoDolutegravir Sodium/Lamivudine35$118,068
CabenuvaCabotegravir/Rilpivirine14$80,787
TrulicityDulaglutide64$63,364
EdurantRilpivirine Hcl29$41,497
OzempicSemaglutide39$36,770
DelstrigoDoravirine/Lamivu/Tenofov Diso12$30,562
MounjaroTirzepatide30$28,986
MytesiCrofelemer11$26,814
IsentressRaltegravir Potassium15$26,612

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Viiv Healthcare CompanyJuluca, Triumeq, Tivicay, Dovato, Cabenuva$1,226$936,262290 claims
GileadBiktarvy, Descovy$1,598$562,284186 claims
MerckDelstrigo, Isentress, Pifeltro, Isentress Hd$134$106,05254 claims
Lilly USA, LLCTrulicity, Mounjaro$55$92,35094 claims
Janssen Scientific Affairs, LLCEdurant$43$41,49729 claims
Napo Pharmaceuticals IncMytesi$490$26,81411 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 10,533 family medicine providers in California.

Other family medicine in Los Angeles

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →